Skip to content

Replimune Group REPL Preferred Stock, Par or Stated Value Per Share

Preferred Stock, Par or Stated Value Per Share at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
Immunovant, Inc. logo
Immunovant, Inc.IMVT
Summit Therapeutics logo
Summit TherapeuticsSMMT
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
Incyte logo
IncyteINCY

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+28.6%
Enterprise value$885.15M+28.3%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockParOrStatedValuePerShare.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's preferred stock, par or stated value per share.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's preferred stock, par or stated value per share?
Replimune Group (REPL) reported preferred stock, par or stated value per share of $0 in Q4 2025.
How has Replimune Group's preferred stock, par or stated value per share changed year-over-year?
Replimune Group's preferred stock, par or stated value per share decreased by 0.0% year-over-year, from $0 to $0.